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There is controversy over whether traditional intermittent bolus dosing or continuous infusion of beta-lactam
antibiotics is preferable in critically ill patients. No significant difference between these two dosing strategies in
terms of patient outcomes has been shown yet. This is despite compelling in vitro and in vivo pharmacokinetic/
pharmacodynamic (PK/PD) data. A lack of significance in clinical outcome studies may be due to several
methodological flaws potentially masking the benefits of continuous infusion observed in preclinical studies. In this
review, we explore the methodological shortcomings of the published clinical studies and describe the criteria that
should be considered for performing a definitive clinical trial. We found that most trials utilized inconsistent
antibiotic doses and recruited only small numbers of heterogeneous patient groups. The results of these trials
suggest that continuous infusion of beta-lactam antibiotics may have variable efficacy in different patient groups.
Patients who may benefit from continuous infusion are critically ill patients with a high level of illness severity. Thus,
future trials should test the potential clinical advantages of continuous infusion in this patient population. To further
ascertain whether benefits of continuous infusion in critically ill patients do exist, a large-scale, prospective,
multinational trial with a robust design is required.
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Introduction
The mortality rate of severe sepsis and septic shock in
critically ill patients remains high despite recent thera-
peutic advances. Swift and judicious antibiotic use in
these patients is vital and any delays are associated with
increases in mortality [1,2]. Beta-lactam antibiotics are
used commonly and are regarded as a cornerstone in the
management of critically ill patients with severe sepsis in
intensive care units (ICU) around the world [1,3,4].
However, the occurrence of severe pathophysiological
changes, namely the fluid shift phenomenon [5] and
augmented renal clearance [6], in critically ill patients
may alter the pharmacokinetics (PK) of the antibiotics.
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in any medium, provided the original work is pto prevent inadequate antibiotic concentrations and thera-
peutic failure [5,7,8].
Antibiotic pharmacodynamics (PD) is the discipline
that attempts to relate PK parameters to the ability of an
antibiotic to kill or inhibit the growth of bacterial patho-
gens [9]. Antibiotics can be classified based on these PD
characteristics. Generally, antibiotics are classified into
three categories based on their mode of bacterial killing:
(1) concentration-dependent; 2) time-dependent; or 3)
both (Figure 1). The first category includes antibiotics,
such as aminoglycosides, where the best predictor of ef-
ficacy is the ratio of peak drug concentration (Cmax) to
minimum inhibitory concentration (MIC; Cmax/MIC)
[10,11]. Some antibiotics, such as fluoroquinolones and
glycopeptides, are more complex and exhibit both a con-
centration and time-dependent kill characteristics where
the best predictor of efficacy is the ratio of area under
the concentration time curve during a 24-hour period
(AUC0-24) to MIC (AUC0-24/MIC). Therefore, increasing
the dose or/and concentration for these antibiotics can
be logically expected to enhance the rate and extent ofis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 2 The simulated concentration-time profile of a beta-
lactam antibiotic when administered by intermittent bolus
dosing or continuous infusion (Vd= 0.22 L/kg; T1/2 = 2.45 hr).














Figure 1 Pharmacokinetic and pharmacodynamic parameters of antibiotics on a concentration vs. time curve. T>MIC, time that a drug’s
plasma concentration remains above the minimum inhibitory concentration (MIC) for a dosing period; Cmax, maximum plasma antibiotic
concentration; AUC0-24, area under the concentration-time curve during a 24-hour time period.
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concentrations do not significantly influence their effi-
cacy. Based on numerous in vitro and in vivo experi-
mental data, it is the duration of effective antibiotic
exposure that is more important for these time-
dependent antibiotics [14-17].
The debate persists about whether traditional intermit-
tent bolus dosing (IB) or continuous infusion (CI) is
clinically preferable for administration of beta-lactam
antibiotics. This is despite the fact that beta-lactam PD
data suggest advantages for CI compared with IB [18-24],
showing time-dependent activity and demonstrating that
the duration of time (T) the free drug concentration
remains above the minimum inhibitory concentration
(MIC; fT>MIC) best describes its bacterial kill characteris-
tics [15] (Figure 1). Thus, administration via CI should
be advantageous, because it inevitably produces higher
and sustained antibiotic concentrations above the MIC.
It also is noteworthy that IB yields unnecessary high peak
and low trough concentrations below MIC for much of
the dosing interval [25-28] (Figures 2 and Figures 3). The
constant and sustainable antibiotic concentrations pro-
vided by CI are particularly important for pathogens with
high MIC values. Such pathogens are relatively common
in the ICU [29-31].
Despite these theoretical advantages, a global practice
shift toward CI of beta-lactam antibiotics has not taken
place. This is mostly because, although CI has been
shown to be superior to IB dosing during in vitro [32,33]
and in vivo [34-37] experimental studies, comparative
clinical studies have so far failed to demonstrate signifi-
cant differences in patient outcome. Furthermore, three
recent meta-analyses of these clinical trials have found simi-
lar outcomes between CI and IB, in heterogeneous hospita-
lized patient populations [38-40]. This dissociation betweenpreclinical data and clinical reports raises uncertainty for
the treating clinician. Importantly, most trials have import-
ant methodological flaws and have used inconsistent meth-
ods and therapeutic endpoints [29]. There also is a lack of
general consensus about which patient groups should be
investigated and the appropriate methodology that should
be employed to identify whether clinical outcome differ-
ences between these two dosing approaches exist in all
hospitalized patients. The possible advantages and disad-
vantages from the two dosing methods are further summa-
rized in Table 1.
The purpose of this review is to describe the published
clinical trials and their associated methodological short-
comings in their comparison of CI and IB administration
in hospitalized patients. Several intriguing issues or pro-
blems involved in the interpretation of results obtained
Figure 3 Observed steady-state plasma and tissue concentrations for meropenem administered to critically ill patients with sepsis by
intermittent bolus dosing and continuous infusion (adapted from Roberts et al. 2009, J Antimicrob Chemother). Continuous infusion (CI)
meropenem plasma concentration (solid dark lines); IB meropenem plasma concentration (dotted grey lines); IB meropenem interstitial fluid
concentration (ISF) (solid grey lines); CI meropenem ISF concentration (dotted dark lines).
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based on these discussions, description of a methodologic-
ally robust, definitive clinical trial will be proposed.
PK/PD considerations
The percentage (%) of fT>MIC (% fT>MIC) during a dosing
interval is regarded as the optimal PD index for beta-
lactam antibiotics, and as such, maintaining effective
drug concentration above the MIC should be the priority
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studies [44,45]. Thus, it has been suggested that maintain-
ing concentrations above the MIC for 90-100% of the dos-
ing interval is a rational PD endpoint to ensure that the
above minimum targets are achieved [46]. Combining the
above data, beta-lactams should be more effective when
delivered continuously to achieve a level above the MIC
continuously throughout treatment. Alternatively, prolong-
ing the infusion time via extended-infusion (EI), also has
been suggested to maximize the fT>MIC for this antibiotic
class without some of the CI-associated drawbacks outlined
in Table 1 [47,48]. Both CI and EI may be particularly ad-
vantageous in the treatment of severe infections.Inconsistent PD endpoints for comparison
Different PD endpoints have been used in published
studies, which make comparison between CI and IB dif-
ficult. However, several reviews have suggested that pro-
longed antibiotic exposures will achieve better PD
profile [7,49,50]. Apparent benefits with regards to max-
imum bacterial killing also were reported in several studies
when antibiotic concentrations were maintained above the
MIC for extended periods, ideally four to five times the
MIC especially when less susceptible microorganisms were
involved [33,44,51-55]. In combination with other PK/PD
data, it is suggested that therapeutic targets for CI therapy
should be a steady-state concentration (Css) that is at least
4 x MIC [33]. Thus, future comparative PK/PD studies
should evaluate the relative ability of IB to achieve a trough
concentration (Cmin) greater than the 4 x MIC of the
offending pathogen for 40–70% of a dosing interval and for
CI, a Css greater than 4 x MIC to prevent biased compari-
sons. It follows that the real challenge for IB is to obtain a
Cmin greater than 4 x MIC in a severely ill patient who is
infected with a pathogen with high MIC.The role of postantibiotic effect
Another consideration for optimizing antibiotic pharma-
cokinetic exposure is the postantibiotic effect (PAE), i.e.,
the suppression of bacterial growth even with antibiotic
concentrations below the MIC [56]. Although all antibio-
tics demonstrate PAE against susceptible gram-positive
pathogens (i.e., staphylococci and streptococci), only some
antibiotics, such as the aminoglycosides and fluoroquino-
lones produce prolonged PAE for gram-negative pathogens
[15]. In contrast, beta-lactams except for the carbapenems,
produce minimal or no PAE against gram-negative patho-
gens. It follows that the reduced % fT>MIC required for car-
bapenems bacteriostatic (20%) and bactericidal (40%)
activity may relate to the antibiotics PAE [56-61]. There-
fore, the need for frequent dosing and continuous adminis-
tration is deemed supplemental when antibiotics such as
carbapenems display significant PAE.Revision in antibiotic breakpoints
The recent revision in antibiotic breakpoints to indicate
if an organism is susceptible or resistant to different
antibiotics, as classified by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST; available
at http://www.eucast.org/clinical_breakpoints/) and Clin-
ical and Laboratory Standards Institute (CLSI; available
at http://www.clsi.org/) have had an impact on how cli-
nicians view and manage infections worldwide. These
new rules also are applicable for interpretation of anti-
biotic PK/PD studies. Due to these changes, future studies
need to be interpreted in light of the new susceptibility
breakpoints [62]. These new rules may mean that the
present dosing approaches are more or less likely to
achieve PK/PD targets [29].
The role of optimal PK/PD targets in the prevention of
antibiotic resistance
Antibiotic resistance patterns have significantly changed
during the past 15 years with increasing resistance currently
regarded as a major health crisis [63,64]. Furthermore, the
rate at which the pathogens are currently developing anti-
biotic resistance is likely to far outpace the rate of develop-
ment of new antibiotics. Thus, optimizing the use of new
or existing antibiotics via PK/PD principles may prolong
their lifespan in clinical practice [42,57]. Although numer-
ous studies have been performed to determine the optimal
PK/PD targets for clinical and bacteriological success, very
little data exist that describe their roles in the prevention
of bacterial resistance. However, extensive research in this
area has been conducted with fluoroquinolones and more
importantly, the corresponding optimal PD targets (i.e.,
AUC/MIC breakpoints) for resistance prevention has been
described for this antibiotic class [65-67]. The success with
fluoroquinolones further emphasizes that PK/PD principles
are not only relevant in bacterial eradication but also should
be considered to minimize the development of bacterial re-
sistance. For the beta-lactams, however, limited data are
currently available, with the exception of several in vitro
[68,69] and in vivo experimental studies [70], which suggest
the optimal PD targets for the prevention of resistance.
Thus, appropriate targets are initially needed for this
antibiotic class before a dosing regimen that minimizes
resistance development can be recommended. Until
convincing evidence becomes available, antibiotic dos-
ing that targets concentrations greater than 4–6 x MIC
for an extended interval should be aimed at to prevent
resistance [33,71,72]. It also follows that once the tar-
gets are defined, it will then be possible to evaluate the
relative ability of CI vs. IB in reducing the emergence of
resistance associated with the use of beta-lactam anti-
biotics. However, several reviews have suggested that
the currently proposed PK/PD target is probably best
achieved by using CI or EI [29,46].
Abdul-Aziz et al. Annals of Intensive Care 2012, 2:37 Page 5 of 16
http://www.annalsofintensivecare.com/content/2/1/37Controversies surrounding data interpretation
Since the initial availability of antibiotics, methods to
optimize antibiotic dosing have been explored [17,73].
Numerous trials have been conducted with beta-lactams
testing various dosing strategies in various patient popu-
lations [52,74-89]. The characteristics and findings of these
relevant clinical trials are described in Tables 1 and 2, re-
spectively. However, these studies have not defined
whether altered dosing approaches are advantageous and
which patient groups may benefit. Most of these trials
were conducted in North America and Europe between
1979 and 2008 with all but two studies published after the
year 2000 [88,89]. A number of articles also have dis-
cussed the potential advantages and disadvantages of CI
[29,31,46,90,91]. Yet, the limitations of the existing studies
have not been analyzed in detail and require further ela-
boration. Figure 4 briefly summarizes the current limita-
tions associated with the available clinical trials.
Heterogeneous patient populations
Most of the relevant trials recruited hospitalized
patients from different populations, especially the non-
critically ill patient groups (Table 2). The diverse range
of patient groups include critically ill patients with sep-
sis [75,78,80,84,85,87,88], trauma patients [86], patients
with abdominal infections [79,82], chronic obstructive
pulmonary disease (COPD) patients [76,83], cancer
[89], and nonspecific hospitalized infections [81]. Thus,
meta-analyses have evaluated heterogenous patient groups
and any potential benefits of CI or IB that may exist in a
particular patient group were not assessed. This issue was
previously discussed by Roberts et al. in their meta-analysis,
where large confidence intervals were observed suggesting
clinical differences may exist between CI and IB administra-
tion if more stringent and rigorous inclusion criteria were
used in clinical studies [39].
Inclusion of patients with a low level of illness severity
Detecting significant difference between CI and IB is dif-
ficult because the potential benefits may be masked by
the inclusion of low-risk patients that have much lower
mortality rates than reported in epidemiological studies.
This selection bias was further described in two recent
meta-analyses [38,39]. For example, two of the nine ICU
studies that were meta-analyzed by Roberts et al.
reported a mortality rate <10% when the mortality rate
for severe sepsis is usually reported between 40% and
50% [92-94] (Table 3). Other studies also recruited
patients with low illness severity whereby more than 70% of
the cohort presented with an Acute Physiological and
Chronic Health Evaluation II (APACHE II) score of only 10
[79]. This is a problem because any differences between CI
and IB are more likely emerge in more severely ill patients
[45,87]. Critically ill patients with severe sepsis are morelikely to benefit from CI, because they commonly develop
severe pathophysiological changes, which may reduce ef-
fective antibiotic exposure [95]. Furthermore, these patients
are usually infected with pathogens that are less susceptible
to antibiotic therapy. Thus, in combination, the two im-
portant factors may reduce PK/PD target attainment in se-
verely ill patients. In contrast, it has been shown that IB
dosing of beta-lactam antibiotics achieves adequate PK/PD
target for bacterial eradication in patients with low level of
illness severity.Inconsistent antibiotic dosing regimen
Most of the studies included in the three meta-analyses
utilized higher IB doses than the CI treatment arm, po-
tentially favoring the former [76-79,81,84,86,87] (Table 3).
This treatment bias might have skewed the results of these
meta-analyses towards the null hypothesis. Another logical
conclusion is that a lower dose in the CI group was able to
achieve equivalent outcomes to a higher dose in the IB
group. A significant difference in clinical outcomes might
emerge if the two approaches utilized the same daily dose.
This notion has been supported by a meta-analysis,
whereby clinical failures were less frequent in the CI group,
when separate analyses were performed in trials which
used the same total daily dose in the two treatment arms
[40]. Furthermore, dosing inconsistency with regards to
initial bolus administration of antibiotic was reported in
several studies [80,82,85] (Table 3). An initial loading dose
was not provided to the CI protocol in these studies. This
approach delays attainment of target antibiotic concentra-
tions compared with the IB group. To make the two dosing
protocols comparable, an initial and equal loading dose of
beta-lactam antibiotic should be provided to both groups.Pathogens with low MIC values
The offending pathogens isolated in most of the clinical
trials have MIC values that make them highly suscep-
tible. Simulation data suggests that there will be little
difference in the achievement of PK/PD targets for IB
and CI if the pathogens involved are in the susceptible
range. When less susceptible pathogens are present, the
true potential benefits of CI may be seen because treat-
ment failures are more likely with IB [27,44,57,87]. This
limitation has been highlighted in the two most recent
meta-analyses and has been proposed as one of the con-
tributing reasons why clinical differences between CI
and IB of beta-lactams have not been found. This notion
is supported by one randomized, clinical trial [87] and
two retrospective, observational studies [45,96], which
were conducted in critically ill patients infected with
gram-negative organisms. These studies reported clinical
cure and mortality benefits favoring CI for pathogens
with high MIC values.
Table 2 Characteristics of previously published studies for CI vs. IB of beta-lactam antibiotics















Angus et al. [87] Not specified (Thailand) Ceftazidime Yes Septicemic
melioidosis
21 48 (29–58) 43 (27–73) Not specified Not specified Not specified Amx/clv or
doxy, tmp/smx
and chlora
Bodey et al. [89] Non-ICU (USA) Cefamandole No Malignant
diseases with
neutropenia
204 Not specified Adequate Adequate Not specified Carbenicillin
Buck et al. [81] Non-ICU (Germany) Pip/tazo No Hospitalized
infections
24 60-88b 32-76b Not specified Adequate No Nil stated
Buijk et al. [52] ICU (Netherlands) Ceftazidime Yes Intra-abdominal
infections
18 12 (46–76) 6 (42–87) Not specified Not specified No Various
Georges et al. [80] ICU (France) Cefepime Yes Critically ill with
gram-negative
infections
50 50 ± 17 46 ± 24 Not specified Not specified No Amikacin
Hanes et al. [86] ICU (USA) Ceftazidime Yes Critically ill trauma 32 33.5 ± 12.5 36.1 ± 12.8 Not specified Not specified No Nil stated
Kojika et al. [82] Not specified (Japan) Meropenem No Intra-abdominal
infections
10 67.4 ± 14.6 60 ± 12.8 Not specified Not specified No Nil stated
Lagast et al. [88] Not specified (Belgium) Cefoperazone No Gram-negative
septicaemia
45 37-77b Not specified Not specified No Nil stated
Lau et al. [79] ICU (USA) Pip/tazo No Complicated intra-
abdominal
infections
262 50.4 ± 16.6 49.3 ± 17.8 Not specified Not specified No Nil stated




81 65.3 ± 10.1 Not specified Not specified No Nil stated
Nicolau et al. [84] ICU (USA) Ceftazidime Yes Critically ill
patients with
sepsis
41 46 ± 16 56 ± 20 Adequate Not specified No Tobramycin
Pedeboscq et al. [85] ICU (France) Pip/tazo Yes Severe sepsis 7 58 ± 12 Not specified Not specified No Ofloxacin
Rafati et al. [78] ICU (Iran) Piperacillin Yes Critically ill
patients with
sepsis
40 50.1 ± 22.2 48.0 ± 20.7 Not specified Not specified No Amikacin
Roberts et al. [75] ICU (Australia) Ceftriaxone Yes Critically ill
patients with
sepsis
57 43 ± 19 52 ± 16 Adequate Adequate Adequatec Multiple
depending on
indication
Sakka et al. [77] ICU (Germany) Imi/cila Yes Critically ill
patients with
sepsis




















Table 2 Characteristics of previously published studies for CI vs. IB of beta-lactam antibiotics (Continued)




93 65.3 ± 8.4 68.6 ± 5.3 Not specified Not specified No Nil stated
CI, continuous infusion; IB, intermittent bolus; Amx/clv, amoxicillin/clavulanic acid; doxy, doxycycline; tmp/smx, trimethoprim/sulphamethoxazole; chlora, chloramphenicol; pip/tazo, piperacillin/tazobactam; Imi/cila,
imipenem/cilastatin; COPD, chronic obstructive pulmonary disease.
aValues are described as published results as mean (±SD) or median (range).





















Figure 4 The summary of the current limitations and flaws associated with the available clinical trial.
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Another noteworthy limitation is that patients included
in the available clinical trials were frequently prescribed
concomitant antibiotics that, unrelated to the method of
beta-lactam administration, may influence clinical out-
come [38,40]. Such additional antibiotics (aminoglycosides
and fluoroquinolones) provide adequate antimicrobial
coverage for most gram-negative pathogens. Therefore,
the exclusive contribution of beta-lactam antibiotics to
patient outcomes will be poorly defined in these trials.
However, in reality, beta-lactam antibiotics are usually
administered in conjunction with an aminoglycosides
especially when treating patients with severe infections.
It follows that regardless of the beta-lactam administra-
tion method, the aminoglycosides or fluoroquinolones
may be “protecting” patients from gram-negative patho-
gens during periods of inadequate beta-lactams concen-
tration. A plausible explanation could be that the
method of administering beta-lactams is not that im-
portant when additional gram-negative coverage (i.e.,
aminoglycosides or fluoroquinolones) is used.
Insufficient sample sizes
The lack of significance in the published results also
may be attributed to the consistently small sample sizes
that have been used to explore the effect of CI vs. IB.
The typical study cohort size has varied from 10 to 531
patients but the majority of these trials studied less than
60 patients [52,75,77,78,80-82,84,86,88] (Table 2). Thesmall sample sizes and heterogenous patient background
in the clinical studies contribute to insufficient power to
investigate the value of both dosing methods. Further to
this, if the population of interest is critically ill patients,
a single intervention in this setting in very unlikely to in-
fluence mortality and clinical cure [31] and, as a conse-
quence, a much larger sample size is needed to show
significance [21,40,80]. For instance, Roberts et al. calcu-
lated that a sample size of 560 patients in each dosing
protocol would be needed to detect difference in bac-
teriological outcomes [75]. Considering the difficulties in
achieving these numbers in critically ill patients, perhaps
it is time for clinicians to fully acknowledge the import-
ance of surrogate endpoints in the setting of a study.
Clinical cure and ICU-free days are suitable surrogate
endpoints and may be used as primary outcomes in a
phase II study of this intervention.
Other relevant concerns
Apart from the discussion above, there are several other
plausible reasons why clinical differences have not been
established between CI and IB in previous trials. It is im-
portant to note that some patients, especially in the
ICU, may have some degree of renal impairment on ad-
mission or during their hospital stay [97-99]. Whereas a
commonly prescribed beta-lactam dose may not be suffi-
cient in patients with mild or no renal impairment, tar-
get antibiotic concentrations are more easily achieved in
patients with moderate to advanced renal impairment
Table 3 Antibiotic dosage and outcome data of previously published for CI vs. IB of beta-lactam antibiotics
Study Types of infection Number of patients
(APACHE scorea)






CI IB p value
CI IB CI IB
Angus et al. [87] Melioidosis 10 (15) 11 (21) 12 mg/kg LD, then
4 mg/kg every 1 hr
40 mg/kg every 8 hr Yes Mortality 20% 36.4% 0.89
Bodey et al. [89] Pneumonia, UTI, septicemia
and neutropenic fever
167 (ND) 162 (ND) 3 g LD, then
12 g/24 hr
3 g every 6 hr No Clinical cure 64.8% 56.5% ND
Buck et al. [81] Pneumonia, cholangitis and
FUO
12 (ND) 12 (ND) 2 g LD then
8 g/24 hrb
4 g every 8 hrb Yes Clinical
response
67% 67% ND
Buijk et al. [52] Intra-abdominal infections 12 (16) 6 (14) 1 g LD then
4.5 g/24 hr
1.5 g every 8 hr Yes Mortality 25% 33% 1.0
Georges et al. [80] Pneumonia and septicemia 24 (45c) 23 (44c) 2 g/12 hrs twice
daily
2 g every 12 hr Yes Mortality 12% 13% NDd
Clinical cure 85% 67% NDd
Duration of
MV
24± 13 25.3 ± 10 NDd
LOS ICU 34± 17 40 ± 15 NDd
Hanes et al. [86] Pneumonia 17 (13) 14 (11) 2 g LD then 60 mg/
kg every 24 hr
2 g every 8 hr Yes Duration of
MV
22.9 ± 19.9 13.3 ± 6.1 0.16
LOS ICU 26.8 ± 20.1 15.5 ± 5.9 0.11
LOS Hospital 41.7 ± 30.5 28.7 ± 15.9 0.37
Duration of
leukocytosis
7.8 ± 7.3 11.3 ± 4.7 0.35
Duration of
pyrexia
7.9 ± 4.4 4.3 ± 2.5 0.06
Kojika et al. [82] Abdominal abscess 5 (ND) 5 (ND) 0.5 g every 8 hr
(over 3 hr)
0.5 g every 8 hr
(over 30 min)
No Mortality 20% 0%
Lagast et al. [88] Septicemia 20 (ND) 25 (ND) Day 1: 1 g LD then
3 g/24 hr Day 2 +:
4 g/24 hr
2 g every 12 hr No Mortality 25% 16% ND
Clinical cure 70% 80% ND
Lau et al. [79] Abdominal infections 81 (8) 86 (8) 2 g LD
then 12 g/24 hre
3 g every 6 hre No Mortality 0.76% 2.6%




Lubasch et al. [83] Chronic bronchitis 41 (ND) 40 (ND) 2 g LD then
2 g/7 hr twice daily




Nicolau et al. [84] Pneumonia 17 (14) 18 (16) 1 g LD then
3 g/24 hrf
2 g every 8 hrf No Clinical cure 41% 33% 0.592
Duration of
MV




















Table 3 Antibiotic dosage and outcome data of previously published for CI vs. IB of beta-lactam antibiotics (Continued)
LOS ICU 8.5 ± 3.4 9.3 ± 4.0 0.691
Time to
defervescence
3.1 ± 2.1 5.2 ± 2.3 0.015
WBC
normalization
7.3 ± 3.0g 5.5 ± 4.2g 0.259
Pedeboscq et al. [85] Gastrointestinal-related
infections
3 (ND) 4 (ND) 12 g/24 hr 4 g every 8 hr Yes Mortality 0% 0% ND
Rafati et al. [78] Pneumonia, UTI, abdominal
infections, SSI and septicemia
20 (16) 20 (14) 2 g LD then
8 g/24 hr










Roberts et al. [75] Septicemia 29 (19) 28 (16) 0.5 g LD then
2 g/24 hr
Day 1: 2.5 g/24 hr
Day 2: 2 g/24 hr
No Mortality 10% 0% 0.25
Clinical curei 52% 20% 0.04
Duration of
MV
4.3 ± 4.5 3.4 ± 4.1 0.33
LOS ICU 10.8 ± 23.2 5.6 ± 6.0 0.29
LOS hospital 42 ± 6.9 24 ± 2.1 0.34
Sakka et al. [77] Pneumonia 10 (26) 10 (28) 1 g LD then
2 g/24 hr
1 g every 8 hr Yes Mortality 10% 20% ND
Van Zanten et al. [76] COPD exacerbations 40 (ND) 43 (ND) 1 g LD then
2 g/24 hr
1 g every 8 hr Yes Clinical cure 93% 93% 0.93
APACHE, Acute Physiology and Chronic Health Evaluation score; CI, continuous infusion; IB, intermittent bolus; PK/PD, pharmacokinetic/pharmacodynamic; UTI, urinary tract infection; FUO, fever of unknown origin; SSI,
surgical site infection; COPD, chronic obstructive pulmonary disease; ND, not described; LD, loading dose; MV, mechanical ventilation; LOS, length of stay; ICU, intensive care unit; WBC, white blood cells.
aValues are reported as mean.
bDose reduction in renal dysfunction-if creatinine clearance 25–60 mL/min (CI group 6.75 g/24 hr; IT group 4.5 g q12hr); if creatinine clearance <25 mL/min (CI group 4.5 g/24 hr; IB group 4.5 g every 24 hr).
cValues are SAPS II score.
dP values for nonsignificance were not reported.
eDose reduction in renal dysfunction-if creatinine clearance 20–40 mL/min (CI group 8 g-1 g/24 hr; IB group 2 g −0.25 g every 6 hr).
fDose reduction in renal dysfunction-if creatinine clearance 31–50 mL/min (CI group 2.5 g/24 hr; IB group 2 g every 12 hr); if creatinine clearance 21–30 mL/min (CI group 2 g/24 hr; IB group 2 g every 24 hr).
gx 109/L.
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equate in patients with significant renal impairment as
antibiotic clearance is reduced, regardless of the drug
administration method [19]. Finally, one of the strongest
bodies of evidence suggesting the superiority of CI has
been derived from in vivo or animal models. However,
the metabolic pathways and tissue distribution patterns
of an antibiotic in animals may differ from humans. In
addition, more often than not, these animal models fail
to mimic human sepsis [101,102].
Based on the discussion above, clearer insights regard-
ing CI and IB administration in patients receiving beta-
lactam antibiotics are emerging. Importantly, the results
from previous clinical studies suggest that CI of beta-
lactam antibiotics is unlikely to be advantageous for all
hospitalized patients but may be important in specific
patient cohorts. Thus, in an attempt to elucidate the true
benefits, we contend that the patient population most
likely to adequately test the putative benefits of continu-
ous administration of beta-lactam antibiotics must in-
volve 1) critically ill patients; 2) patients with higher
level of illness severity (i.e., APACHE II score ≥ 15); 3)
patients infected with less susceptible microorganisms;
and 4) patients with gram-negative infections.
Methodology concerns and the proposed characteristics
of an “ideal” trial
Several reviews have suggested the importance of designing
and conducting a methodologically sound clinical trial in
the investigation of CI versus IB antibiotic administration
benefits in critically ill patients [29,38-40]. These recom-
mendations cannot be overemphasized due to frequent
reports of low methodological quality clinical studies. It also
is noteworthy that a previous study, which utilized the most
rigorous and stringent methods, was the only study to dem-
onstrate a clinical cure advantage in favor of CI administra-
tion of beta-lactams [75]. The characteristics of an “ideal,”
randomized, clinical trial to compare CI vs. IB administra-
tion of beta-lactam antibiotics in critically ill patients are
described in Table 4.
Most studies did not address the methods for allo-
cation sequence generation and concealment further in-
creasing the chance for selection bias [74,76,78-88]
(Table 2). In many studies, masking or blinded assessment
of the study endpoints were not adequately addressed caus-
ing detection bias [74,76-84,86-89] (Table 2). In addition,
most of the available studies have failed to have blinded
clinicians to assess the clinical and bacteriological out-
comes. Each of these issues increases the possibility of sys-
tematic errors in these studies.
Ideally, the antibiotic dosing regimen in each treat-
ment arm (i.e., CI and IB) should be comparable in
terms of the provision of an initial loading dose with an
equal daily antibiotic dose. Alternatively, a suitablesurrogate endpoint, such as a cost-effective analysis, may
be used to compare these two dosing approaches when
unequal antibiotic doses are used between them. Con-
comitant administration of other non-beta-lactam antibio-
tics, such as the aminoglycosides or fluoroquinolones, in
the setting of a study is appropriate considering that a
single empirical therapy is unlikely to occur during
antibiotic initiation in ICU patients [1,4]. Furthermore,
the concomitant administration of other antibiotics
should be regarded as a limitation rather than a major
flaw in future trials, because it reflects real clinical
practice. However, the number of concomitant antibiotics
that are used and their administration sequences in relation
to the main study antibiotic should at least be described in
the trials.
Only a number of studies measured the antibiotic con-
centrations and included a concurrent PK/PD evaluation
to confirm whether the dosing approaches were actually
meeting their respective PK/PD endpoints (Table 3)
[52,76-79,86]. Hence, it is difficult to relate clinical out-
comes to the respective antibiotic exposure obtained via
the two approaches. It is imperative to note the differ-
ence in PK/PD endpoints with regards to CI and IB. In a
comparison that reflects current practice, CI has to
achieve a steady-state antibiotic concentration (Css)
greater than 4 x MIC to be microbiologically more ef-
fective than IB. On the other hand, IB has to achieve an
antibiotic concentration (Cmin) greater than 4 x MIC
during the typical 40–70% of the dosing interval
[29,33,87,103]. Therefore, concentrations measurement
and concurrent PK/PD analysis needs to be done in light
of this information or the extent of antibiotic exposure
may not occur as predicted and therefore the influence
on clinical cure and mortality will never be understood.
However, the concurrent analysis should only be consid-
ered “compelling” in future trials as long as contributing
clinical sites have the necessary infrastructure to ensure
apt antibiotic sampling. Errors in sampling, which are
common in PK/PD studies, may result in inaccurate and
faulty assessments with regards to the apparent benefits
of either dosing approaches.
Considering the rampant development of bacterial re-
sistance, the exact role of altered dosing approaches to
reduce the problem should be addressed. To date, stud-
ies investigating the impact of various beta-lactams dos-
ing approaches and their associated risk of bacterial
resistance are scarce [72]. However, it is interesting to
note the findings of a recent prospective, multicenter, ran-
domized study that compared the clinical benefits of EI
doripenem vs. IB imipenem in patients with ventilator-
associated pneumonia [74]. The authors reported that only
18% of patients treated with EI developed resistance of
P. aeruginosa compared with 50% who received the con-
ventional imipenem dosing. This is one of the few recent
Table 4 Description of a randomized clinical trial that should be performed to investigate CI vs. IB beta-lactam
antibiotics
Criteria Comments
Population Should only include patients with sepsis or severe sepsis
Intervention Antibiotic dosing regimen should be similar between CI and IB group
a. A loading dose should be given to continuous infusion group to ensure rapid attainment of target antibiotic concentration
b. An equal daily antibiotic dose should be given to continuous and bolus administration group
c. Antibiotic doses should be specified according to the patient’s body weight
d. Concomitant administration of other non-beta-lactam antibiotics should be allowed
PK/PD analysis Concurrent PK/PD analysis should be performed to support any findings
a, Measurements of antibiotic concentrations should be performed as long as contributing sites have necessary infrastructure
to ensure apt sampling
b. PK/PD analysis should evaluate the relative ability of IB to achieve a Cmin greater than 4 x MIC of the offending pathogen
for 40-70% of the dosing interval while for CI, a Css greater than 4 x MIC
Methods Design
Preferably multicenter in nature and recruits participants from different regions to improve generalizability of results
Patients
Define eligibility criteria for participants to be included into trial
a. Definition of sepsis and severe sepsis should be described in detail
b. Inclusion and exclusion criteria used should be explained
Randomization
Detailed explanation on allocation sequence generation development
Detailed allocation concealment mechanism
Blinding/masking
Outcome evaluators for the trial should be blinded to participants management
Endpoints
a. Endpoints selection should include primary (clinical outcome) and secondary (PK/PD; adverse event) endpoints
b. Data collection on the observed bacterial resistance in the two treatment arms should occur
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approaches in the prevention of resistance; similar stud-
ies, particularly involving critically ill patients, should
ensue. Although there are not enough prior clinical data
to power a study in the ICU and describe the appropri-
ate methodology, data collection on the observed resist-
ance should be performed in future clinical trials
investigating the two dosing approaches.
Previously published studies have mostly been single-
center in design. To our knowledge, only three studies
were conducted as a multicenter study, and only two of
the three studies were able to include more than 200
patients [74,79,83]. The need for more multicenter stud-
ies should be emphasized, because these studies will pro-
vide a stronger basis for subsequent generalization of
any findings. Participation from different regions and
countries in such studies also should be encouraged to
facilitate generalization even more to an extent of a pos-
sible global practice change.
Because of the cost of large-scale trials, a step-wise ap-
proach to consider potential problems and feasibility isdesirable. An initial pilot study before proceeding with a
larger multicenter trial is beneficial. In this regard, the
Beta-lactam Infusion Group’s feasibility study (BLING I)
has now led to the design of large clinical outcome
study, BLING II. BLING I (Dulhunty et al., unpublished
results; ACTRN12610000238077) was a prospective, mul-
ticenter, double-blind, double dummy, pilot, randomized,
controlled trial enrolling 60 critically ill patients from 5
ICUs across Australia and Hong Kong. The primary end-
point of the study was to establish the PK separation be-
tween CI and IB in terms of achieving plasma antibiotic
concentrations above the MIC of causative pathogens.
The PK findings in BLING I demonstrated significant dif-
ferences in plasma antibiotic concentrations above MIC
favoring the CI group (CI; 81.8% vs. IB; 28.6%, p=0.001),
thus supporting the notion of PK/PD superiority asso-
ciated with continuous administration. Clinical cure also
was superior in the CI group (CI; 70.0% vs. IB; 43.3%,
p= 0.037). Other relevant findings include the feasibility of
the proposed randomization and blinding process used by
the BLING I investigators and the suggestion of
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in a multicenter study. Thus, based on the findings from
BLING I, BLING II was designed with rigorous and strin-
gent methods to answer the ultimate question of whether
administration of beta-lactam antibiotics by CI will result
in improved outcomes for patients with severe sepsis.
BLING II is a phase II, multicenter, double-blinded, ran-
domized, controlled trial that will recruit critically ill
patients with severe sepsis in several ICUs in New Zealand
as well as Australia and Hong Kong. The Australian Na-
tional Health and Medical Research Council (NHMRC)-
funded clinical trial aims to compare the effects of two
approaches to the administration of beta-lactam antibio-
tics (i.e., CI vs. IB) on ICU-free days up to day 28.
Conclusions
Although numerous PK/PD data from various in vitro
and in vivo experimental studies favor the use of con-
tinuous infusion, the current clinical data are less con-
vincing and insufficient to instigate a global shift from
conventional bolus dosing. However, this lack of convin-
cing data may be due to several methodological flaws
and inconsistencies among the available studies, thus
contributing toward insufficient power to detect any sig-
nificant differences between CI and IB, if they exist.
Based on the published literature, it can be concluded that
CI of beta-lactams will not be beneficial to all patients but
may potentially be beneficial to specific subsets of patients.
If any patient group is likely to benefit from CI, it may be
critically ill patients with severe infections. If benefits from
CI do exist in critically ill patients, a large-scale, prospective,
multinational trial with a robust design is required. A step-
wise approach to conduct such clinical trials has begun and
already shows promise. A phase II study involving 420
patients is about to start and will provide high-quality infor-
mation to confirm or refute the need for a pivotal phase III
double-blinded RCT of CI vs. beta-lactam dosing in critic-
ally ill patients with sepsis.
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